ESLA
Estrella Immunopharma, Inc.
There isn't enough reported data to score ESLA yet.
ESLA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ESLA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ESLA PE Valuation
ESLA has no meaningful PE right now: it lost money over the past year.
ESLA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ESLA's losses to shrink, with revenue holding steady.
ESLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.24 | +$0.09 |
ESLA lost $0.24 per share over the past year, a smaller loss than the year before.
ESLA Quarterly Revenue
ESLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.8M | -$1.4M |
| Q1 2026 | -$6.7M | -$6.2M |
| Q4 2025 | -$177.5K | +$718.6K |
| Q3 2025 | -$727.3K | +$1.5M |
| Q2 2025 | -$414.9K | -$123.4K |
| Q1 2025 | -$466K | +$3.8M |
| Q4 2024 | -$896.1K | +$10.4M |
| Q3 2024 | -$2.2M | -$1.9M |
ESLA has burned cash in almost every quarter: −$9M over the past year, against −$4M the year before.
ESLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +877K shares |
| 1 year | +19% | +6.8M shares |
ESLA has 43M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $29,462 |
| Q4 2024 | $64,012 |
| Q2 2021 | — |
| Q1 2021 | — |
ESLA Net Leverage
ESLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ESLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 29.8 | Neutral |
ESLA's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
ESLA PE vs Healthcare Sector
ESLA has no meaningful PE right now: it lost money over the past year.
ESLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.54 | 3.7% below |
| 20 week MA | $0.66 | 21% below |
| 50 week MA | $1.04 | 50% below |
| 100 week MA | $1.12 | 54% below |
| 200 week MA | $2.90 | 82% below |
ESLA is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
ESLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.80 | $9.85 | +0.5% |
| 2022 | $9.85 | $10.3 | +4.5% |
| 2023 | $10.3 | $1.11 | -89% |
| 2024 | $1.11 | $1.27 | +14% |
| 2025 | $1.27 | $1.54 | +21% |
| 2026 YTD | $1.54 | $0.52 | -66% |
ESLA is down 66% so far in 2026, after finishing higher in four of the previous five years.